✦ LIBER ✦

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

✍ Scribed by de Boer, R. H.; Arrieta, O.; Yang, C.-H.; Gottfried, M.; Chan, V.; Raats, J.; de Marinis, F.; Abratt, R. P.; Wolf, J.; Blackhall, F. H.; Langmuir, P.; Milenkova, T.; Read, J.; Vansteenkiste, J. F.

Book ID: 125518995
Publisher: American Society of Clinical Oncology
Year: 2011
Tongue: English
Weight: 295 KB
Volume: 29
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2010.29.5717

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9004 Vandetanib plus pemetrexed vs pemet

9004 Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

✍ Vansteenkiste, J.; Arrieta, O.; Gottfried, M.; Blackhall, F.H.; Raats, J.; Yang, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

9001 Vandetanib plus docetaxel versus do

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

✍ Eberhardt, W.E.E.; Johnson, B.E.; Sun, Y.; Germonpré, P.; Saijo, N.; Zhou, C.; W 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Vandetanib plus docetaxel versus docetax

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

✍ Roy S Herbst; Yan Sun; Wilfried EE Eberhardt; Paul Germonpré; Nagahiro Saijo; Ca 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 327 KB

9005 Vandetanib versus erlotinib in pati

9005 Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

✍ Goss, G.D.; Thongprasert, S.; Greco, F.A.; Thomas, M.; Tsai, C.M.; Sunpaweravong 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

The Role of Vandetanib in the Second-Lin

The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials

✍ Wei-Xiang Qi; Li-Na Tang; Ai-Na He; Zan Shen; Yang Yao 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 320 KB

Phase III, Randomized, Double-Blind, Pla

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer

✍ Paz-Ares, L. G.; Biesma, B.; Heigener, D.; von Pawel, J.; Eisen, T.; Bennouna, J 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 163 KB